Search results
Valsartan vs. Losartan: Similarities & Differences
Verywell Health via Yahoo News· 6 months agoHypertension (HBP, high blood pressure) is a common medical condition affecting 48% of adult Americans. Left untreated, high blood pressure can lead to...
First it was blood pressure medication. Now FDA eyes more drugs for cancer-causing chemical.
USA TODAY via Yahoo News· 1 year agoFor people managing high blood pressure, recalls of the carcinogen-tainted drug quinapril might...
Cardurion’s PDE9 inhibitor increases cGMP in Phase IIa heart failure trial
Clinical Trials Arena via Yahoo Finance· 3 days agoCardurion Pharmaceuticals has said its phosphodiesterase-9 (PDE9) inhibitor, CRD-740, has met the...
US Court Issues Negative Decision On Novartis' Heart-Failure Drug Patent
Benzinga via Yahoo Finance· 10 months agoSwiss pharma giant Novartis AG (NYSE: NVS) announced that the U.S. District Court for the District...
Novartis (NVS) Gets CHMP Positive Opinion for Entresto Approval
Zacks via Yahoo Finance· 1 year agoNovartis NVS announced that its cardiovascular drug Entresto (sacubitril/valsartan) has received a...
Novartis Is Tracking Well Above the Industry
GuruFocus.com via Yahoo Finance· 2 weeks agoNovartis AG (NYSE:NVS) is one of the largest pharmaceutical companies in the world, many of whose drugs are "gold standards" in the treatment of cancer,...
Novartis (NVS) Entresto Patent Faces Setback, Stock Down
Zacks via Yahoo Finance· 10 months agoNovartis NVS recently received an unfavorable ruling from the U.S. District Court for the District...
The secret to breaking down the high price of prescription drugs
WPXI via Yahoo News· 2 years agoAn investigation has uncovered the secret to many newer name-brand medications. Some of these...
How Is Heart Disease Treated?
Health via Yahoo News· 1 year agoMedically reviewed by Angela Ryan Lee, MD Heart disease can be treated with options like medications or lifestyle changes. Treatment depends on several...
Novartis (NVS) to Report Q3 Earnings: What's in the Offing?
Zacks via Yahoo Finance· 7 months agoInvestor focus is likely to be on the top and bottom-line numbers, and updates on guidance...
